Article
A common druggable signature of oncogenic c-Myc, mutant KRAS and mutant p53 reveals functional redundancy and competition among oncogenes in cancer.
Cell death & disease - 31 Aug 2024
Grześ Maria, Jaiswar Akanksha, Grochowski Marcin, Wojtyś Weronika, Kaźmierczak Wojciech, Olesiński Tomasz, Lenarcik Małgorzata, Nowak-Niezgoda Magdalena, Kołos Małgorzata, Canarutto Giulia, Piazza Silvano, Wiśniewski Jacek R, Walerych Dawid
Abstract excerpt
The major driver oncogenes MYC, mutant KRAS, and mutant TP53 often coexist and cooperate to promote human neoplasia, which results in anticancer therapeutic opportunities within their downstream molecular programs. However, little research has been conducted on whether redundancy and competition among oncogenes affect their programs and ability to drive neoplasia. By CRISPR‒Cas9-mediated downregulation we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.